[Innovative therapeutic approaches for hereditary neuromuscular diseases]

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Significant advancements in understanding neuromuscular disease genetics and pathophysiology.
• Development of novel, mutation-specific therapeutic strategies.

Purpose of the Study:

• To review current and emerging therapeutic approaches for neuromuscular diseases.
• To highlight the importance of post-marketing surveillance for orphan drugs.

Main Methods:

• Splicing modification using antisense oligonucleotides.
• Read-through of premature stop codons.
• Gene therapy via viral vectors.
• Optimization of enzyme replacement therapies.

Main Results:

• First drugs approved for Duchenne muscular dystrophy and spinal muscular atrophy.
• Promising preclinical and clinical development for myotubular myopathy, myotonic dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease.

Conclusions:

• New therapeutic avenues offer hope for rare neuromuscular disorders.
• Systematic post-marketing follow-up is essential for assessing the safety and efficacy of newly approved, often expensive, orphan drugs due to limited initial evidence.